About OnCusp

OnCusp Therapeutics is a global biopharmaceutical company translating a focused portfolio of first-in-class oncology assets from promising research into proven medicines. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp completed a $25m seed round from investors including Sequoia Capital China, BioTrack Capital, Oriza Seed Capital, and AIHC Capital. OnCusp has offices in New York and Shanghai.

We deliver

help and hope to

cancer patients worldwide.

Culture and Values

The OnCusp Therapeutics team has deep experience in the science and business of global medical innovation. We have shaped our company culture to draw on this knowledge, combining crisp, goal-oriented strategy with an emphasis on societal benefit and win-win partnerships. Our team works quickly but holds each other accountable so that quality is never compromised. We take smart risks and bet big when the situation calls for it. We value honesty. We structure our partnerships to share risk and reward in a fair, transparent manner while working to maximize value using our deep experience and global networks. We always keep an eye on results, not only in terms of value creation but, importantly, on our vision of the societal bottom line—the improved patient outcomes our work enables.

Company Milestones

  • Apr 2022

    Established global partnership (excluding China) with a Chinese biotech, to develop CUSP06

  • Oct 2021

    Established global partnership (excluding China) with a Chinese biotech to discover and develop CUSP03

  • Sept 2021

    Initiation of first In-House Program CUSP02

  • Aug 2021

    Established global partnership with a US biotech to develop CUSP01

  • Jun 2021

    Opened New York office

  • Apr 2021

    Opened Shanghai office

  • Apr 2021

    - Company Founded
    - Completed $25 million seed round financing and started operations

Management Team

Scientific Advisory Board